H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

Drug Target Review

OCTOBER 1, 2024

Since I was a child, I always wanted to be a doctor. From a human point of view, I have always considered doctors’ work as a sort of mission for the good of others. Being a doctor means giving courage and hope day in, day out to those experiencing illness.

Doctors 64

Doctors Therapies Science Pharma Companies 64

H1 Blog

NOVEMBER 15, 2023

Since KOLs play such a critical role, engaging with the right KOLs is a key strategy for pharmaceutical companies to stay ahead of the game. Compliance ensures that interactions between pharmaceutical companies and KOLs are transparent, fair, and free from any undue influence.

Compliance 59

Compliance Science Regulations Pharmaceutical Companies 59

Alta Sciences

MARCH 27, 2024

Eryn has a wealth of expertise in diverse therapeutic areas and, after her experiences with battling cancer, a commitment to advancing the pharmaceutical industry by merging conventional and alternative treatments into one model. Get to know Eryn with this Q&A: What motivated you to pursue a doctorate degree? Then fate intervened.

Drug Development 52

Drug Development Medical Schools Pharma Companies Drugs 52

The Pharma Data

NOVEMBER 27, 2020

This week, another pharma company revealed a new technology device that can detect if a patient is infectious or not, while the Russian government published results of its Sputnik V vaccine, claiming it is more than 95 per cent efficient 42 days after the first dose.

Virus 52

Virus Vaccine International Immune Response 52

Elrig

APRIL 29, 2024

big pharma or startups/spin off? thanks Big pharma experienced is very well respected within biotech or small-startups. Interactive Q&A session: Pose your questions directly to the experts and get tailored insights to your interests and concerns. Where do you enjoy more to work? What pro/cons?

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Codon

FEBRUARY 13, 2024

3 Another considerable obstacle to pharmaceutical companies’ interest (and investment) is the fact that for a product to be patentable — and therefore profitable — it has to be considered new and inventive. UTIs, diabetic foot ulcers).

Therapies 120

Therapies DNA Virus Clinical Trials 120